EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Relief Therapeutics Holding EBITDA Margin % Related Terms
Relief Therapeutics Holding EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RLFTF vs KTTA, OSRH, LIMN: EBITDA Margin % Comparison
For the Biotechnology subindustry, Relief Therapeutics Holding's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relief Therapeutics Holding EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Relief Therapeutics Holding's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relief Therapeutics Holding (RLFTF) has a EBITDA Margin % of -302.94% as of Jun. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Relief Therapeutics Holding and its competitors.
Is Relief Therapeutics Holding's EBITDA Margin % too high?
Relief Therapeutics Holding's current EBITDA Margin % is -302.94%. Overall, Relief Therapeutics Holding has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Relief Therapeutics Holding's EBITDA Margin % compare to KTTA and OSRH?
Relief Therapeutics Holding's EBITDA Margin % of -302.94% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Relief Therapeutics Holding and its competitors. Relief Therapeutics Holding's current EBITDA Margin % is -302.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relief Therapeutics Holding stock overvalued right now?
Relief Therapeutics Holding (RLFTF) has a current EBITDA Margin % of -302.94%. The stock's GF Value™ is $0.61, compared to a current price of $0.29 — trading 53.3% below its estimated fair value. The current EBITDA Margin % is -302.94%. Relief Therapeutics Holding's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Relief Therapeutics Holding (RLFTF), the current EBITDA Margin % is -302.94% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Relief Therapeutics Holding (RLFTF) Overvalued in 2026?
Based on GuruFocus' analysis, Relief Therapeutics Holding stock appears to be undervalued.
The current stock price of $0.29 is trading 53.3% below its estimated GF Value™ of $0.61.
Key valuation signals for RLFTF:
EBITDA Margin %: -302.94%
GF Value™: $0.61 vs. price of $0.29 (53.3% below fair value)
No single metric tells the full story. See the RLFTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
31GF Score
Get the complete analysis for RLFTF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RLFTF has been successfully added to your 
